Payton Harris, Heart Transplant Recipient, Battles Insurer After Anti-Rejection Drug Denial

Young Transplant Recipient Fights To Keep Donor heart Alive After Insurer Denies Medication

USA: A Dayton woman who received a heart transplant as a child is confronting a new battle in her twenties after her insurer initially denied coverage for a long‑standing anti‑rejection drug. Payton Harris, born with congenital heart problems, received a donor heart on March 18, 2012, after a sudden deterioration and a blood clot found in her right atrium on March 2, 2012. She had been taking the anti‑rejection medication everolimus for more than a decade, a therapy her transplant team deemed necessary to prevent organ rejection.

The coverage fight began when Blue Cross Blue Shield/Blue Anthem sent a denial letter asserting that everolimus was not medically necessary for a heart transplant and citing differences from kidney or liver transplant protocols. Treating physicians disagreed with the insurer’s assessment. As her prescription supplies dwindled during back‑and‑forth appeals, Harris turned to social media to share her predicament and the potential risk to the transplanted organ that has kept her alive since age 11.

Public attention and personal appeals produced a response: the insurer reversed course, approved the medication and issued an apology while saying it would review internal processes to better assess individual members’ needs. Harris reported steep out‑of‑pocket prices during the dispute, noting a 30‑day supply carrying a $350 price tag and a longer supply priced well beyond her ability to pay. The mother of the 24‑year‑old donor, identified only as Christian, also intervened, offering to help cover costs after learning Harris faced difficulty maintaining the therapy that protects the donated heart.

The episode highlights the precarious intersection of long‑term transplant care, prescription affordability and insurer review practices. Harris’s case advances from a pediatric emergency to an adult stewardship of a donated life — a trajectory that now depends as much on benefit approvals and drug pricing as on surgical success and medical surveillance.